Cargando…

AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors

BACKGROUND: Optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs. METHODS: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chang-Lu, Zhao, Yi-Zhuo, Zhang, Qin, Zeng, Wan-Qin, Jia, Tian-Ying, Zhu, Lei, Fang, Wen-Tao, Fu, Xiao-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792827/
http://dx.doi.org/10.21037/med-22-ab002
_version_ 1784859718760529920
author Wang, Chang-Lu
Zhao, Yi-Zhuo
Zhang, Qin
Zeng, Wan-Qin
Jia, Tian-Ying
Zhu, Lei
Fang, Wen-Tao
Fu, Xiao-Long
author_facet Wang, Chang-Lu
Zhao, Yi-Zhuo
Zhang, Qin
Zeng, Wan-Qin
Jia, Tian-Ying
Zhu, Lei
Fang, Wen-Tao
Fu, Xiao-Long
author_sort Wang, Chang-Lu
collection PubMed
description BACKGROUND: Optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs. METHODS: Patients with progression disease after failure of platinum-based chemotherapy were enrolled in this study. Anlotinib was orally taken once a day at an initial dose of 12 mg (10 mg when body weight <60 kg). The cycle was repeated every 3 weeks (2 weeks of treatment followed by 1 week rest). There are 3 dose levels (12, 10 and 8 mg), and dose may be reduced to a lower level when grade 3 toxicity occurred. Objective response rate (ORR) and progression-free survival (PFS) were recorded as primary end points, and they were analyzed separately in thymoma (THY) and thymic carcinoma (TC) cohorts. Meanwhile, toxicities were assessed according to CTCAE (version 5.0). RESULTS: There were 50 patients enrolled in this study from October 2018 to June 2021 at a median age of 50 (range, 23–79) years old. Patients with THY and TC were 33 (66%) and 17 (34%) respectively. The ORR in THY and TC patients were 33% (11/33) and 41% (7/17), respectively. The median PFS (mPFS) were 7 (95% CI: 5.9–10.2) months in THY patients and 6 (95% CI: 4.6–9.3) months in TC group. Eleven patients experienced dose reduction due to toxicities, among whom, 8 patients discontinued treatment even after dose reduction. Six patients with THY showed myasthenia gravis (MG) deterioration during treatment, and 2 of them died of MG crisis. CONCLUSIONS: Anlotinib is active in patients with advanced TETs refractory to routine chemotherapy. Prescription of Anlotinib to patients with MG should be made cautiously.
format Online
Article
Text
id pubmed-9792827
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-97928272022-12-30 AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors Wang, Chang-Lu Zhao, Yi-Zhuo Zhang, Qin Zeng, Wan-Qin Jia, Tian-Ying Zhu, Lei Fang, Wen-Tao Fu, Xiao-Long Mediastinum Abstract BACKGROUND: Optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs. METHODS: Patients with progression disease after failure of platinum-based chemotherapy were enrolled in this study. Anlotinib was orally taken once a day at an initial dose of 12 mg (10 mg when body weight <60 kg). The cycle was repeated every 3 weeks (2 weeks of treatment followed by 1 week rest). There are 3 dose levels (12, 10 and 8 mg), and dose may be reduced to a lower level when grade 3 toxicity occurred. Objective response rate (ORR) and progression-free survival (PFS) were recorded as primary end points, and they were analyzed separately in thymoma (THY) and thymic carcinoma (TC) cohorts. Meanwhile, toxicities were assessed according to CTCAE (version 5.0). RESULTS: There were 50 patients enrolled in this study from October 2018 to June 2021 at a median age of 50 (range, 23–79) years old. Patients with THY and TC were 33 (66%) and 17 (34%) respectively. The ORR in THY and TC patients were 33% (11/33) and 41% (7/17), respectively. The median PFS (mPFS) were 7 (95% CI: 5.9–10.2) months in THY patients and 6 (95% CI: 4.6–9.3) months in TC group. Eleven patients experienced dose reduction due to toxicities, among whom, 8 patients discontinued treatment even after dose reduction. Six patients with THY showed myasthenia gravis (MG) deterioration during treatment, and 2 of them died of MG crisis. CONCLUSIONS: Anlotinib is active in patients with advanced TETs refractory to routine chemotherapy. Prescription of Anlotinib to patients with MG should be made cautiously. AME Publishing Company 2022-12-30 /pmc/articles/PMC9792827/ http://dx.doi.org/10.21037/med-22-ab002 Text en 2022 Mediastinum. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Abstract
Wang, Chang-Lu
Zhao, Yi-Zhuo
Zhang, Qin
Zeng, Wan-Qin
Jia, Tian-Ying
Zhu, Lei
Fang, Wen-Tao
Fu, Xiao-Long
AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
title AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
title_full AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
title_fullStr AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
title_full_unstemmed AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
title_short AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
title_sort ab002. anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792827/
http://dx.doi.org/10.21037/med-22-ab002
work_keys_str_mv AT wangchanglu ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors
AT zhaoyizhuo ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors
AT zhangqin ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors
AT zengwanqin ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors
AT jiatianying ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors
AT zhulei ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors
AT fangwentao ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors
AT fuxiaolong ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors